Compare · AGL vs LSTA
AGL vs LSTA
Side-by-side comparison of agilon health inc. (AGL) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $1.64B, about 107.5x LSTA ($15.2M).
- LSTA has been more active in the news (5 items in the past 4 weeks vs 3 for AGL).
- AGL has more recent analyst coverage (25 ratings vs 0 for LSTA).
- Company
- agilon health inc.
- Lisata Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.64B
- $15.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 5
- Recent ratings
- 25
- 0
AGL
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Latest AGL
- agilon health downgraded by Citigroup with a new price target
- agilon health inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- agilon health Sets Date to Report Second Quarter 2026 Financial Results
- Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 2,311 shares, decreasing direct ownership by 2% to 138,031 units (SEC Form 4) to satisfy tax liability
- agilon health to Participate in Upcoming Conferences
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 485 shares, decreasing direct ownership by 0.73% to 66,112 units (SEC Form 4) (tax liability)
- Director Wulf John William was granted 2,133 shares, increasing direct ownership by 15% to 16,765 units (SEC Form 4)
- Director Williams Ronald A was granted 2,133 shares, increasing direct ownership by 1% to 149,141 units (SEC Form 4)
- Director Mcloughlin Karen was granted 2,133 shares, increasing direct ownership by 35% to 8,207 units (SEC Form 4)
- Director Mckenzie Diana was granted 2,133 shares, increasing direct ownership by 39% to 7,633 units (SEC Form 4)
Latest LSTA
- Lisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- SEC Form SC 14D9 filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement